This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

How to Get Stock Exposure to Gluten-Free Movement

Stocks in this article: RIBT

NEW YORK (TheStreet) -- The gluten-free diet movement is all over the news and, more importantly, in more and more restaurants. Reports estimate the size of the gluten-free market to be anywhere from $500 million to $10 billion. That's a rather large expanse, but just view it as growth potential.

A gluten-free diet excludes foods containing a protein composite found in wheat, barley, rye and triticale. It is also the only medically accepted treatment for celiac disease, an illness attacking the small intestine due to the presence of gluten. 

There are a few publicly traded companies that sell products aimed largely at consumers honing to a gluten-free diet. They are stocks with small market capitalizations, meaning that share liquidity is low, volatility can be high, factor that can make such stocks difficult or risky to trade. 

RiceBran Technologies (RIBT) is a human-food ingredient and animal nutrition based in Scottsdale, Ariz. focused on the procurement, bio-refining and marketing of products derived from rice bran. Rice Bran Technologies has proprietary and patented intellectual property that allows it to convert rice bran, one of the world's most underutilized food sources, into a number of highly nutritious human food ingredient and animal nutrition products.

RiceBran sells products which are used by food manufacturers to create gluten free, hypoallergenic, minimally processed and non-GMO, nutrition-rich products used in pasta, baked goods, pizza dough, cereals, ground meats, healthy beverages and numerous other applications.

RiceBran generated $35 million in revenue in 2013, though it wasn't profitable on the basis of earnings before interest, taxes, depreciation and amortization, or EBITDA, a widely-followed metric. The 2014 forecast is for 69% revenue growth and $2 EBITDA per share. RiceBran has approximately 3 million shares outstanding and a market capitalization of approximately $19 million. 

A second stock focused on the gluten-free market is Senomyx  (SNMX) discovers, develops and commercializes flavor ingredients for packaged foods and beverage. The San Diego-based company has a market capitalization of $319 million and has forecasted revenue to fall in the range of $32 million to $35 million for 2014, generated a loss of about $10 million to $12 million.

Amira Nature Foods (ANFI) , which is based in Dubai, United Arab Emirates, engages in processing, distributing, and marketing packaged specialty rice and other food products. Amira has a market capitalization of $459 million and trades at trailing 12-month EV/EBITDA of 9.1.

If RiceBran were to trade at 5 times its 2014 EBITDA, it would be a $10 stock, and at 10 times its 2014 EBITDA, the stock would trade at $20. RiceBran is as a nice way to get exposure to the gluten-free diet movement, which is why I'm long on the stock.

At the time of publication, the author owned ANFI.

This article represents the opinion of a contributor and not necessarily that of TheStreet or its editorial staff.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,232.34 +163.47 0.96%
S&P 500 2,001.75 +29.01 1.47%
NASDAQ 4,619.0820 +71.2480 1.57%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs